Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016

Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016
Published Jun 22, 2016
116 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016, provides in depth analysis on Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted pipeline therapeutics.

The report provides comprehensive information on the Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30)
- The report reviews Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
- The report assesses Poly (ADP-Ribose) Pol

  
Source:
Document ID
GMDHC0105TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD (+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Overview101
Therapeutics Development114
  Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Stage of Development111
  Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Therapy Area121
  Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Indication132
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Companies176
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Universities/Institutes232
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Therapeutics Assessment256
  Assessment by Monotherapy/Combination Products251
  Assessment by Mechanism of Action261
  Assessment by Route of Administration272
  Assessment by Molecule Type292
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Companies Involved in Therapeutics Development3115
  AbbVie Inc.311
  American Gene Technologies International Inc.321
  AstraZeneca Plc331
  BeiGene, Ltd.341
  Clovis Oncology, Inc.351
  Eisai Co., Ltd.361
  Hager Biosciences, LLC371
  IMPACT Therapeutics, Inc.381
  Jeil Pharmaceutical Co., Ltd.391
  Jiangsu Hengrui Medicine Co., Ltd.401
  Mitsubishi Tanabe Pharma Corporation411
  Nerviano Medical Sciences S.r.l.421
  Takeda Pharmaceutical Company Limited431
  Tesaro, Inc.441
  Teva Pharmaceutical Industries Ltd.451
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Drug Profiles4647
  ABT-767 Drug Profile461
  AGPD Drug Profile471
  AZ-0108 Drug Profile481
  BGB-290 Drug Profile492
  CK-102 Drug Profile511
  E-7449 Drug Profile521
  fluzoparib Drug Profile531
  IMP-04297 Drug Profile541
  JPI-289 Drug Profile551
  MP-124 Drug Profile561
  niraparib Drug Profile574
  NMSP-118 Drug Profile611
  NMSP-648 Drug Profile621
  NMSP-914 Drug Profile631
  olaparib Drug Profile649
  R-503 Drug Profile732
  rucaparib phosphate Drug Profile757
  Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning Drug Profile821
  Small Molecule to Inhibit PARP-1 for Undisclosed Indication Drug Profile831
  Small Molecules to Inhibit PARP-1 for Colon Cancer Drug Profile841
  Small Molecules to Target PARP1, 2, 3 and NO for Oncology Drug Profile851
  veliparib Drug Profile865
  XZ-120312 Drug Profile911
  YHP-743 Drug Profile921
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Dormant Projects936
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Discontinued Products991
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Featured News &Press Releases10015
  Jun 06, 2016: Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting1003
  Jun 05, 2016: LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer1032
  Jun 04, 2016: TESARO Provides Update on niraparib at ASCO Investor Briefing1051
  Jun 04, 2016: Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation1051
  May 19, 2016: Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting1061
  May 18, 2016: TESARO Announces Three Abstracts on Niraparib to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting1071
  May 18, 2016: AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer1081
  May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 20161091
  Apr 27, 2016: Lynparzatm (Olaparib) Now Available To NHS Patients In England And Wales With BRCA-Mutated Ovarian Cancer1091
  Apr 18, 2016: AstraZeneca Presents New Data On PARP Inhibitor Lynparza (olaparib) at the AACR 2016 Annual Meeting1101
  Apr 14, 2016: Myriad Genetics announces presentation on niraparib study at the 2016 American Association for Cancer Research Annual Meeting1111
  Jan 28, 2016: Lynparza (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer1111
  Jan 27, 2016: NICE recommends olaparib for ovarian cancer1121
  Jan 25, 2016: Clovis Oncology Names Dale Hooks as Chief Commercial Officer, Provides Update On Rucaparib1121
  Dec 11, 2015: NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information1132
Appendix1152
  Methodology1151
  Coverage1151
  Secondary Research1151
  Primary Research1151
  Expert Panel Validation1151
  Contact Us1151
  Disclaimer1161

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Poly-ADP-Ribose-Polymerase-1-ADP-Ribosyltransferase-Diphtheria-Toxin-Like-1-or-PARP-1-or-NAD-ADP-Ribosyltransferase-1-or-ADPRT-1-or-Poly-ADP-Ribose-Synthase-1-or-EC-2-4-2-30-Pipeline-Review-H1-2016-2088-15999>
  
APA:
Global Markets Direct - Market Research. (2016). Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Poly-ADP-Ribose-Polymerase-1-ADP-Ribosyltransferase-Diphtheria-Toxin-Like-1-or-PARP-1-or-NAD-ADP-Ribosyltransferase-1-or-ADPRT-1-or-Poly-ADP-Ribose-Synthase-1-or-EC-2-4-2-30-Pipeline-Review-H1-2016-2088-15999>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.